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Background: The VELOUR study demonstrated a survival benefit for FOLFIRI + aflibercept versus FOLFIRI + placebo
in metastatic colorectal cancer (mCRC) patients who progressed on oxaliplatin-based chemotherapy. Continued
divergence of overall survival (OS) curves in the intension to treat (ITT) population, with the survival advantage
persisting beyond median survival time, suggested subpopulations might have different magnitudes of survival
gain. Additionally, 10% of patients within VELOUR had recurrence during or within 6 months of completing
oxaliplatin-based adjuvant therapy (adjuvant fast relapsers) - previously identified as having poorer survival
outcomes.
Methods: To determine which patients received the greatest benefit from FOLFIRI-aflibercept, a post hoc
multivariate analysis of the VELOUR ITT population was conducted. Prognostic factors identified were applied to the
ITT population, excluding adjuvant fast relapsers, to derive OS prognostic profiles.
Results: The better efficacy subgroup was identified as patients within VELOUR exclusive of adjuvant fast relapsers
and had performance status (PS) 0 with any number of metastatic site or PS 1 with <2 metastatic site. A significant
improvement in efficacy outcome was observed with aflibercept in the better efficacy subgroup. Median OS for
FOLFIRI-aflibercept and FOLFIRI-placebo:16.2 and 13.1 months (adjusted Hazard Ratio [HR] = 0.73; 95% confidence
interval [CI]: 0.61–0.86); median progression free survival (PFS): 7.2 and 4.8 months (adjusted HR = 0.68; 95% CI:
0.57-0.80); and objective response rate (ORR): 24% versus 11% respectively. Poorer efficacy subgroup comprised of
adjuvant fast relapsers or patients with PS2 or PS1 with ≥2 metastatic sites. In poorer efficacy subgroup, no benefit
was seen with aflibercept. Median OS for FOLFIRI-aflibercept and FOLFIRI-placebo: 10.4 and 9.6 months (adjusted
HR = 0.97; 95% CI: 0.78-1.21) respectively with no improvement in PFS or ORR.
Conclusion: This analysis suggests that within VELOUR, patients in the better efficacy subgroup may derive
enhanced benefit from treatment with FOLFIRI-aflibercept. These prognostic criteria may guide practitioners toward
optimal use of targeted biologicals in appropriate second-line mCRC patients.
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Colorectal cancer (CRC) accounts for more than 1.2 mil-
lion new cancer cases and over 600,000 deaths [1]. Among
these cases, approximately 25% of patients present with
metastatic CRC (mCRC) at diagnosis and up to half of all
patients with CRC will develop metastases during the
course of their disease [2]. Metastatic unresectable CRC is
generally incurable and has a 5-year survival rate of only
10-15% [3,4]. In most patients the disease will progress on
initial treatment, and up to half of all patients with mCRC
will receive second- and third-line treatments [2,5]. Better
second-line treatments for mCRC are currently needed in
this crucial area of high unmet medical need.
A number of treatment options exist for patients whose
disease progresses after initial therapy [2,6,7], and current
real-world treatment patterns show that targeted agents
plus standard second-line chemotherapy are commonly
utilised [5]. Aflibercept (known as ziv-aflibercept in the
United States) is a novel fusion protein containing vascu-
lar endothelial growth factor (VEGF)–binding portions
from the extracellular domains of human VEGF receptors
1 and 2, fused to the Fc portion of human immuno-
globulin (Ig) G1. Aflibercept blocks the activity of VEGFA,
VEGFB, and placental growth factor (PlGF) by acting as a
high-affinity ligand trap, preventing these ligands from
binding to their endogenous receptors [8]. Aflibercept is
a new option in the second-line treatment of mCRC
and compared to placebo, it has demonstrated statis-
tically significant improvements in overall survival
(OS) (median 13.50 versus 12.06 months; hazard ratio
[HR] = 0.817, p = 0.0032), progression-free survival (PFS)
(6.90 versus 4.67 months; HR = 0.758, p < 0.0001), and
overall response rate (ORR) [19.8% (95% confidence
interval [CI]: 16.4-23.2) versus 11.1% (95% CI: 8.5-13.8);
p < 0.0001] when used in combination with FOLFIRI
(5-fluorouracil-leuocovorin-irinotecan) in patients with
mCRC that is resistant to or has progressed after an
oxaliplatin-containing regimen [9]. The pre-specified
subgroup analyses in the VELOUR trial showed a con-
sistent benefit of aflibercept across all major subgroups,
including patients who had previously received bevacizu-
mab treatment [10]. Continued divergence of OS curves
in the intention to treat (ITT) population, with the sur-
vival advantage persisting beyond median survival time,
suggested subpopulations might have different magnitudes
of survival gain.
The identification of patients who are likely to derive
more benefit from targeted anti-angiogenic therapies has
become increasingly crucial. Despite more than a decade
of intense research effort, no tissue-based predictive
biomarkers have yet been established for anti-angiogenic
therapy. An optimised treatment approach involving care-
ful patient selection based on identified prognostic factors
and known tumor characteristics may enable a moretailored approach to individual treatment. A growing
body of evidence indicates that patient characteristics,
such as age, performance status, time to recurrence fol-
lowing adjuvant therapy, extent of metastases, and use
of prior therapies, can all have an impact on treatment
efficacy in mCRC [2]. With these advances in the know-
ledge of prognostic factors in mCRC, there exists an
opportunity in the real-world setting to target patient
populations based on clinically relevant phenotypes and
prognostic variables. The objective of this post hoc sub-
group analysis described herein was to identify a “better
efficacy” patient population within VELOUR study that
may have derived greater clinical benefit from treatment
with FOLFIRI plus aflibercept.
Methods
This was a post hoc analysis of data from the VELOUR
clinical trial which assessed 1,226 patients with histologi-
cally or cytologically proven colorectal adenocarcinoma
and who had previously received and progressed follow-
ing oxaliplatin-based chemotherapy [9]. A pre-specified
multivariate analysis was conducted on the ITT popu-
lation in the VELOUR trial to identify prognostic fac-
tors associated with improved OS. Trial registration for
VELOUR was NCT00561470 and registration date was
20 November 2007.
Outcome measures
The primary end point of this analysis was OS in the
better and poorer efficacy subgroup of patients identified
in the multivariate analysis. OS was defined as the time
interval from randomisation to death from any cause.
PFS was defined as the time interval from randomisation
to tumor progression or death from any cause, whichever
comes first. Response was assessed according to Response
Evaluation Criteria In Solid Tumors (RECIST) version 1.0
[11] based on independent radiology review, blinded to
patient treatment.
Statistical analyses
Efficacy analyses were conducted in the randomised
population according to the arm to which patients were
assigned at randomisation; response rate was assessed in
the subset of these patients who had measurable disease
at baseline. Safety was analysed using descriptive methods,
in the treated population and subgroups, according to the
treatment received (patients who received ≥1 dose of afli-
bercept were analyzed in the aflibercept arm, regardless of
treatment assignment). Time-to-event parameters were
estimated using Kaplan-Meier analysis [12]. The hazard
ratio (HR) and 95% confidence interval (CI) estimates
were provided using a Cox proportional hazards model
[13]. Covariates used were based on pre-specified sub-
groups, including: Eastern Cooperative Oncology Group
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status, age, prior hypertension, and number of metastatic
organs involved. Formal statistical interaction testing was
performed between treatment and different prognostic
factors at the 2-sided 10% level.
Results
Identification of the better efficacy subgroup
The multivariate analysis identified PS and number of
metastatic sites as key prognostic factors influencing OS
in the VELOUR trial (Table 1). Based on the standardised
literature review, the subgroup of patients who relapsed at
or within 6 months of adjuvant oxaliplatin-based chemo-
therapy (adjuvant fast relapsers; n = 124 patients; ~10% of
ITT population) were excluded in view of their poor prog-
nosis [14]. At the time of regulatory approval by European
Medicine Agency, a survival analysis excluding adjuvant
fast relapsers was specifically requested by the Committee
for Medicinal Products for Human Use and these results
are included in the Summary of Product Characteristics.
Prognostic profiles associated with OS, i.e. PS and
number of metastases (identified from the pre-specified
multivariate analysis), were applied to the ITT popula-
tion after exclusion of adjuvant fast relapsers. To test the
robustness of this prognostic model, the survival of adju-
vant fast relapsers and the non-adjuvant fast relapsers
within VELOUR was examined according to treatment
arm. In non-adjuvant fast relapsers, the HR was 0.78
(95% CI: 0.68-0.90) in favour of aflibercept whereas for
adjuvant fast relapsers, HR was 1.12 (95% CI: 0.72-1.74)
with no survival benefit seen with aflibercept. A qualita-
tive interaction (although not statistically significant)
was noted between treatment and adjuvant fast relapsers
likely due to the relative small number (~10%) of adju-
vant fast relapsers within the VELOUR ITT population.
In the ITT excluding adjuvant fast relapsers popula-
tion, the interaction between the number of organs with
metastases and treatment was significant at the 10% levelTable 1 Results from the pre-specified multivariate Cox
model
Prognostic factors Hazard ratio (95.34% CI) p-value
Treatment: FOLFIRI-aflibercept
versus FOLFIRI-placebo
0.817 [0.713; 0.936] 0.0032
ECOG PS: 1 vs 0 1.683 [1.465; 1.935] < 0.0001
ECOG PS: 2 vs 0 3.625 [2.395; 5.486] <0.0001
Prior bevacizumab: yes vs no 1.165 [1.003; 1.353] 0.0425
Age (years): ≥65 vs <65 1.179 [1.020; 1.363] 0.0233
Prior hypertension: yes vs no 0.785 [0.682; 0.904] 0.0007
Number of metastatic organs
involved as per IRC: >1 vs (0–1)
1.446 [1.258; 1.663] < 0.0001
ECOG, European Cooperative Oncology Group; FOLFIRI, 5-fluorouracil–leucov-
orin–irinotecan; IRC, independent review committee; PS, performance status.in the PS1 subgroup (p = 0.0725), whereas no interaction
was found in the PS0 subgroup (p = 0.5151), indicating
that the treatment effect is different according to the num-
ber of metastatic sites in patients with PS1 but not in pa-
tients with PS0. Based on the strength of association of
the covariates, patients with a performance status of PS0
or PS1 with <2 metastatic site were defined as better effi-
cacy subgroup. Figure 1 shows the construction of the
prognostic profile for the better efficacy subgroup. There-
fore the final better efficacy subgroup was comprised of
patients within VELOUR study exclusive of adjuvant fast
relapsers and had either PS0 with any number of meta-
static sites or PS1 with <2 metastatic site. The interaction
between treatment and the better efficacy subgroup was
statistically significant (p = 0.0147) indicating that there
was a differential OS effect of aflibercept in this better effi-
cacy subgroup compared to placebo. The poorer efficacy
subgroup comprised of patients within VELOUR study
who were adjuvant fast relapsers or PS 1 with ≥2 meta-
static sites or PS2 with any number of metastatic sites.
The better efficacy subgroup consisted of 406 patients
(66%) from the FOLFIRI-placebo control arm and 404
patients (66%) from the FOLFIRI-aflibercept investiga-
tional arm of the VELOUR trial. Table 2 shows baseline
characteristics, which were similar in both study arms.
Within the better efficacy subgroup, 67% of patients re-
ceived no prior treatment with bevacizumab.Efficacy
Figure 2A shows OS for the better efficacy subgroup by
treatment arms. In the better efficacy subgroup, 293/406
patients (72.2%) receiving FOLFIRI-placebo died during
the observation period compared with 244/404 patients
(60.4%) receiving FOLFIRI-aflibercept. There was a signifi-
cant improvement in OS with aflibercept in the better
efficacy subgroup (adjusted HR: 0.73; 95% CI: 0.61-0.86).
The median OS was 13.1 months (95% CI: 11.7-14.2) for
FOLFIRI-placebo-treated patients and 16.2 months (95%
CI: 14.5-18.1) for those treated with FOLFIRI-aflibercept
with an absolute difference of 3.1 months in median OS.
Over time, the magnitude of survival differences be-
tween the 2 treatment groups continued to increase in
the better efficacy subgroup with the absolute OS rate
differences increased from 5% at 6 months to 15% at
30 months (Figure 2A). Table 3 shows a summary of ef-
ficacy results for better and poorer efficacy subgroups
by treatment arms.
Figure 2B shows the OS for the poorer efficacy sub-
group by treatment arms. By contrast, in the poorer
efficacy subgroup, no benefit was seen with afliber-
cept. 167/208 (80.3%) patients receiving FOLFORI-
placebo died during the observation period versus 159/
208 (76.4%) receiving FOLFIRI-aflibercept. The adjusted
Figure 1 Construction of the prognostic profile for the better efficacy subgroup. ECOG: European Cooperative Oncology Group;
OS: overall survival; PS: Performance Status; ITT: Intention to Treat.
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0.97 (95% CI: 0.78-1.21). The median OS was 10.4 months
(95% CI: 9.5-12.1) for FOLFIRI-placebo and 9.6 months
(95% CI: 8.6-11.5) for FOLFIRI-aflibercept. There were no
notable absolute survival differences between the two
treatment arms in the poorer efficacy subgroup (Figure 2B
and Table 3). Figure 3 shows a forest plot of overall sur-
vival for the better and poorer efficacy subgroups. Survival
was similar in the better efficacy subgroup irrespective of
prior bevacizumab use.
In addition, for the better efficacy subgroup, a sig-
nificant improvement in PFS was also observed for
FOLFIRI-aflibercept. The adjusted HR for FOLFIRI-
aflibercept versus FOLFIRI-placebo for PFS was 0.68
(95% CI: 0.57-0.80). Figure 4 shows the PFS for the
better efficacy subgroup by treatment arms. The median
PFS for FOLFIRI-placebo was 4.8 months (95% CI: 4.2-
5.4) compared with 7.2 months for FOLFIRI-aflibercept
(95% CI: 6.8-8.2), an absolute difference of 2.4 months in
median PFS. The absolute difference in 6-month PFS rates
was 25%. Similarly, for the better efficacy subgroup, the
objective response rate (ORR) results followed a consistent
pattern: 23.7% (95% CI: 19.3-28.2) for FOLFIRI-aflibercept
and 11% for FOLFIRI-placebo (95% CI: 7.8-14.3). On the
contrary, no improvements in PFS or ORR were observed
with aflibercept in the poorer efficacy subgroup.Dose intensities were similar between better and poorer
efficacy groups and therefore could not account for the
differential survival effect of aflibercept (Additional file 1:
Table S1). However, as the better efficacy group had a
longer PFS, the mean number of cycles of aflibercept
was more for the better efficacy subgroup.Safety and tolerability
Additional file 1: Table S2 shows adverse reactions and
abnormalities in laboratory values (all grades) reported
at a higher incidence (≥2%) in patients treated with afliber-
cept plus FOLFIRI compared with placebo plus FOLFIRI
in the overall safety population as well as the better and
poorer efficacy subgroups. No notable differences were
seen with all grades and grade 3/4 AEs for the better and
poorer efficacy subgroups compared with the overall safety
population as well as between the two subgroups.
In the better efficacy subgroup, the most commonly
encountered AEs were gastrointestinal in the FOLFIRI-
aflibercept group as was also seen in the entire study
population. Diarrhoea (all grades) occurred in approxi-
mately 70% of patients in the FOLFIRI-aflibercept group
and in approximately 50% of those in the FOLFIRI-
placebo group. Leucopenia (all grades) occurred in
78.5% of patients in the FOLFIRI-aflibercept group and
Table 2 Baseline characteristics of patients in the post hoc subgroup analysis
Parameter Better efficacy subgroup ITT population
FOLFIRI-Placebo FOLFIRI-Aflibercept FOLFIRI-Placebo FOLFIRI-Aflibercept
(n = 406) (n = 404) (n = 614) (n = 612)
Gender, n (%)
Female 174 (42.9) 153 (37.9) 261 (42.5) 247 (40.4)
Male 232 (57.1) 251 (62.1) 353 (57.5) 365 (59.6)
Mean age, y (range) 59.9 (25–86) 59.4 (21–82) 60.2 (19–86) 59.5 (21–82)
Age group, n (%)
<65 y 254 (62.6) 277 (68.6) 376 (61.2) 407 (66.5)
≥65 but <75 y 133 (32.8) 108 (26.7) 199 (32.4) 172 (28.1)
≥75 y 19 (4.7) 19 (4.7) 39 (6.4) 33 (5.4)
Race, n (%)
Asian 29 (7.1) 23 (5.7) 51 (8.3) 35 (5.7)
Black 14 (3.4) 11 (2.7) 27 (4.4) 16 (2.6)
White 355 (87.4) 361 (89.4) 523 (85.2) 548 (89.5)
Other 8 (2) 9 (2.2) 13 (2.1) 13 (2.1)
Cancer diagnosis category, n (%)
Colon 187 (46.1) 188 (46.5) 302 (49.2) 289 (47.2)
Rectosigmoid 95 (23.4) 85 (21) 136 (22.1) 123 (20.1)
Rectum 123 (30.3) 129 (31.9) 174 (28.3) 197 (32.2)
Other 1 (0.2) 2 (0.5) 2 (0.3) 3 (0.5)
Number of organs with metastasis, n (%)
0 2 (0.5) 2 (0.5) 6 (1.0) 2 (0.3)
1 237 (58.4) 230 (56.9) 271 (44.1) 256 (41.8)
>1 167 (41.1) 172 (42.6) 337 (54.9) 354 (57.8)
Metastatic sites, n (%)
Liver 283 (69.7) 294 (72.8) 431 (70.2) 459 (75.0)
Lung 160 (39.4) 152 (37.6) 277 (45.1) 271 (44.3)
Lymph 88 (21.7) 100 (24.8) 181 (29.5) 173 (28.3)
Liver metastasis only, n (%) 134 (33) 141 (34.9) 146 (23.8) 153 (25.0)
ECOG performance status, n (%)
0 314 (77.3) 317 (78.5) 350 (57.0) 349 (57.0)
1 92 (22.7) 87 (21.5) 250 (40.7) 250 (40.8)
2 0 0 14 (2.3) 13 (2.1)
Prior bevacizumab, n (%)
Yes 133 (32.8) 132 (32.7) 187 (30.5) 186 (30.4)
No 273 (67.2) 272 (67.3) 427 (69.5) 426 (69.6)
ECOG, European Cooperative Oncology Group; FOLFIRI, 5-fluorouracil–leucovorin–irinotecan; ITT, intent to treat; PS, performance status.
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group. Stomatitis and hypertension were more common
with FOLFIRI-aflibercept than with FOLFIRI-placebo.
Severe AEs (≥grade 3) reported in the FOLFIRI-aflibercept
arm included diarrhoea, stomatitis, fatigue, hypertension,
and neutropenia. However, the majority of these severe
treatment-associated AEs were grade 3 and included
known VEGF-inhibitor class effects, such as hypertension,proteinuria, and haemorrhage, and known chemotherapy-
associated AEs, such as diarrhoea, stomatitis, infection,
and neutropenia.
As in the overall safety population and the better
efficacy subgroup, in the poorer efficacy subgroup
leucopenia was the most commonly encountered AE
with FOLFIRI-aflibercept. Diarrhoea occurred in appro-
ximately 65% in both groups. Severe AEs (≥grade 3)
Table 3 Summary of efficacy results for better and poorer
efficacy subgroups by treatment arms
Better efficacy subgroup Poor efficacy subgroup
FOLFIRI-
placebo
FOLFIRI-
aflibercept
FOLFIRI-
placebo
FOLFIRI-
aflibercept
Overall survival rates
6 months 83% 88% 71% 70%
12 months 54% 64% 43% 42%
18 months 34% 46% 24% 24%
24 months 22% 35% 12% 15%
30 months 12% 27% 10% 13%
Progression free survival rates
6 months 38% 63%
12 months 15% 20%
18 months 5% 6%
Objective response rates
11% 24%
A
B
Figure 2 Overall survival according to treatment arms.
(A) Better efficacy subgroup (B) Poorer efficacy subgroup.
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rhoea, stomatitis, fatigue, hypertension, and neutropenia.
The incidence of grade ≥3 treatment-emergent AEs
provided were consistent between the 2 subgroups,
with slightly more grade ≥3 vomiting, decreased appe-
tite, and weight loss in the poorer responders subgroup
and more grade ≥3 proteinuria in the better efficacy
subgroup.Discussion
The VELOUR trial demonstrated a statistically signifi-
cant benefit of adding aflibercept to FOLFIRI in terms of
OS, PFS, and ORR when compared with placebo plus
FOLFIRI in the ITT population. This post hoc survival
analysis of the VELOUR study has identified a better ef-
ficacy subgroup that may have an enhanced benefit fromthe addition of aflibercept to FOLFIRI. Data from the
post hoc better efficacy subgroup demonstrated that
patients who received FOLFIRI-aflibercept had a me-
dian OS of 16.2 months (95% CI: 14.5-18.1) compared
with 13.1 months (95% CI: 11.7-14.2) for FOLFIRI-
placebo, a difference of 3.1 months. The adjusted HR
versus FOLFIRI-placebo was 0.73 (95% CI: 0.61-0.86] as
compared to 0.82 (95% CI: 0.71-0.94) in the ITT popula-
tion. In the better efficacy subgroup, survival differences
increased over time reaching 15% at 30 months. The re-
sults for PFS and ORR also followed a consistent pattern
of improvement in the FOLFIRI-aflibercept regimen over
the FOLFIRI-placebo regimen.
The efficacy outcome benefits in the better efficacy
subgroup were obtained without any compromise to
safety, where the AEs in the better efficacy subgroup
closely mirrored those in the overall safety population.
The toxicity profile is in line with expectations for the
anti-VEGF plus chemotherapy class effect seen in other
studies.
With regard to metastases, the primary pre-specified
analysis in the ITT population showed that patients with
liver-only metastases had a better treatment efficacy. In
our post hoc analysis, the prognostic factor identified re-
lated to the number of metastases (≤1 metastasis) and was
not limited to liver-only metastasis or specific metastasis
and sufficed for any organ involvement. Data from current
post-hoc analysis, however, did provide further rationale
to evaluate aflibercept in patients with liver only metas-
tases who require downsizing conversion chemotherapy.
Subgroup analyses in clinical trials are becoming in-
creasingly important to demonstrate the consistency of
the treatment effect and may provide guidance to prac-
tising physicians. Assessment of subgroups is usually
Unadjusted Hazard Ratio Adjusted Hazard Ratio
Figure 3 Forest plot of overall survival for the better and poorer efficacy subgroups. CI, confidence interval. Adjusted HR: Hazard ratio
adjusted on baseline value of performance status, prior bevacizumab, age, hypertension and number of metastatic organs.
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cation at the beginning of a trial. However, given the wide
heterogeneity of treatment effect in relation to tumor bio-
logy and pathophysiology in oncology, well-designed post
hoc analyses in clinical trials aligned with biologic plausi-
bility should be considered an important means to explore
treatment benefits in clinically relevant subpopulations.
The findings of this study are aligned with other
published data in terms of the assessment of clinical
determinants of survival in mCRC. Köhne et al. analyzed
3,825 patients with mCRC who received treatment with
5-fluorouracil in 19 prospective, randomized, controlled
trials, and identified 3 prognostic risk groups based on 4
clinical parameters that included both PS and number
of metastatic sites [15]. PS0 or PS1 was found to be aFigure 4 Progression free survival for the better efficacy subgroup bypositive predictor of overall survival, whereas more than
1 metastatic site was a negative predictor of overall survival.
Díaz et al. subsequently confirmed the application of the
Köhne model in a retrospective study of an mCRC patient
population treated with an irinotecan-based or oxaliplatin-
based chemotherapy and concluded that ECOG PS and
the number of metastatic sites were 2 of the key prognos-
tic factors for predicting OS [16].
The limitations of this study were similar to other
published post hoc analyses. The findings were a result
of a non a priori analysis, and hence could not rule out
selection bias and multiplicity aspects relating to a post
hoc analytic exercise. Thus this post hoc survival ana-
lysis was only hypothesis-generating and the findings
need confirmation in prospective trials.treatment arms.
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The better efficacy subgroup, comprising of patients
within VELOUR study exclusive of adjuvant fast relapsers
and had either PS0 with any number of metastatic sites or
PS1 with <2 metastatic site, might derive enhanced
efficacy benefits (OS, PFS, and ORR) with the combination
of aflibercept and FOLFIRI compared with FOLFIRI alone.
The magnitude of OS benefit in the better efficacy sub-
group appeared numerically higher than that seen in the
ITT population. The identification of this better efficacy
subgroup profile for second-line patients with mCRC may
help to guide practitioners toward targeted use of biologi-
cals for maximal survival gains in clinically relevant
patient populations.
Additional file
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efficacy subgroups by treatment arms. Table S2. Adverse reactions and
abnormalities in laboratory values (all grades) reported at a higher
incidence (≥2%) in patients treated with aflibercept plus FOLFIRI
compared with placebo plus FOLFIRI in the overall safety population as
well as the better and poorer efficacy subgroups.
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